These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33138142)

  • 21. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of invasive diseases: strategies to increase vaccination coverage in children and adolescents.
    Zoppi G; Trucchi C
    J Prev Med Hyg; 2012 Jun; 53(2):125-9. PubMed ID: 23240175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 25. Understanding the Sequelae of Invasive Meningococcal Disease in the United States.
    Marshall GS; McCormick ZL; Johns JS; Verduzco-Gutierrez M; Herrera-Restrepo O; Harrison LH
    Infect Dis Ther; 2024 Nov; 13(11):2213-2220. PubMed ID: 39269567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not.
    Alderfer JT; Moran MM; Srivastava A; Isturiz RE
    Postgrad Med; 2019 Nov; 131(8):551-554. PubMed ID: 31575310
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain.
    Martinón-Torres F; de Miguel ÁG; Ruiz-Contreras J; Vallejo-Aparicio LA; García A; Gonzalez-Inchausti MC; de Gomensoro E; Kocaata Z; Gabás-Rivera C; Comellas M; Prades M; Lizán L
    Infect Dis Ther; 2023 Jan; 12(1):157-175. PubMed ID: 36367677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
    Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vaccination against meningococcal B disease. Public statement of the Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP)].
    Moreno-Pérez D; Álvarez García FJ; Arístegui Fernández J; Cilleruelo Ortega MJ; Corretger Rauet JM; García Sánchez N; Hernández Merino A; Hernández-Sampelayo Matos T; Merino Moína M; Ortigosa Del Castillo L; Ruiz-Contreras J;
    An Pediatr (Barc); 2015 Mar; 82(3):198.e1-9. PubMed ID: 25304451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy).
    Trucchi C; Zoppi G
    J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.